Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02345772
Title Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Western Regional Medical Center
Indications

Her2-receptor positive breast cancer

Therapies

Fulvestrant

Docetaxel + Pertuzumab + Trastuzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.